News >

Frontline Olaparib Maintenance Improves PFS in BRCA+ Pancreatic Cancer

OncLive Staff
Published: Tuesday, Feb 26, 2019

Dr Jose Baselga

José Baselga, MD, PhD
Frontline maintenance therapy with olaparib (Lynparza) significantly reduced the risk of disease progression or death versus placebo in patients with germline BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the pancreas, according to findings from the phase III POLO trial announced by AstraZeneca and Merck (MSD), the codevelopers of the PARP inhibitor.1

Beyond the improvement in progression-free survival (PFS), the companies also reported that there were no new safety signals with olaparib. AstraZeneca and Merck plan to report the specific data from the trial at a future medical meeting.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Publication Bottom Border
Border Publication
x